Doris Quon

3.3k total citations
83 papers, 1.8k citations indexed

About

Doris Quon is a scholar working on Hematology, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, Doris Quon has authored 83 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 49 papers in Hematology, 14 papers in Pulmonary and Respiratory Medicine and 14 papers in Oncology. Recurrent topics in Doris Quon's work include Hemophilia Treatment and Research (49 papers), Platelet Disorders and Treatments (16 papers) and Blood Coagulation and Thrombosis Mechanisms (14 papers). Doris Quon is often cited by papers focused on Hemophilia Treatment and Research (49 papers), Platelet Disorders and Treatments (16 papers) and Blood Coagulation and Thrombosis Mechanisms (14 papers). Doris Quon collaborates with scholars based in United States, Canada and United Kingdom. Doris Quon's co-authors include Patricia J. Johnson, Barbara A. Konkle, Elizabeth F. Neufeld, Leonard A. Valentino, Michael Wang, Christine d’Oliveira, Wing-Yen Wong, Lisa Patrone, Alicja Chybicka and Margaret V. Ragni and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and Journal of Biological Chemistry.

In The Last Decade

Doris Quon

81 papers receiving 1.7k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Doris Quon United States	22	1.1k	371	293	155	146	83	1.8k
Rebecca C. Furze United Kingdom	15	206 0.2×	521 1.4×	121 0.4×	64 0.4×	182 1.2×	22	1.6k
Andrew B. Kelly United States	21	421 0.4×	241 0.6×	117 0.4×	89 0.6×	79 0.5×	48	1.3k
Véronique Pancré France	21	166 0.2×	412 1.1×	154 0.5×	144 0.9×	150 1.0×	49	1.5k
Dorte Christiansen Norway	18	286 0.3×	196 0.5×	95 0.3×	136 0.9×	201 1.4×	38	1.4k
Sophie Iochmann France	21	369 0.3×	493 1.3×	103 0.4×	136 0.9×	90 0.6×	39	1.5k
Nicolas Dulphy France	31	593 0.5×	264 0.7×	97 0.3×	43 0.3×	558 3.8×	69	2.9k
Ramsay Fuleihan United States	29	282 0.3×	407 1.1×	226 0.8×	14 0.1×	277 1.9×	89	2.5k
Lily E. Leiva United States	19	159 0.1×	347 0.9×	151 0.5×	77 0.5×	456 3.1×	43	1.4k
Kalle Söderström Sweden	27	263 0.2×	518 1.4×	56 0.2×	74 0.5×	502 3.4×	39	3.9k
Robert J. Boackle United States	17	236 0.2×	288 0.8×	87 0.3×	24 0.2×	122 0.8×	46	1.2k

Countries citing papers authored by Doris Quon

Since Specialization

Citations

This map shows the geographic impact of Doris Quon's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Doris Quon with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Doris Quon more than expected).

Fields of papers citing papers by Doris Quon

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Doris Quon. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Doris Quon. The network helps show where Doris Quon may publish in the future.

Co-authorship network of co-authors of Doris Quon

This figure shows the co-authorship network connecting the top 25 collaborators of Doris Quon. A scholar is included among the top collaborators of Doris Quon based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Doris Quon. Doris Quon is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Leavitt, Andrew D., Johnny Mahlangu, Emily Symington, et al.. (2025). Efficacy and safety of valoctocogene roxaparvovec 4 years after gene transfer in GENEr8-1. Hämostaseologie. 45.

Gordon, Erlinda M., Sant P. Chawla, Vaishali Kumar, et al.. (2024). Seven year update on SOC-1702: A phase 2 study using trabectedin (T) in combination with ipilimumab (I), nivolumab (N) and trabectedin (T) in previously untreated patients with advanced soft tissue sarcoma.. Journal of Clinical Oncology. 42(16_suppl). 11577–11577. 2 indexed citations

Quon, Doris, Shannon Jackson, María Román, et al.. (2024). Long-term clinical outcomes of prophylaxis with an rFVIIIFc or rFIXFc in adults aged ≥50 years with hemophilia A or B. Blood Advances. 8(18). 4751–4755. 1 indexed citations

Quon, Doris, Jiaan‐Der Wang, Michael Wang, et al.. (2024). Outcomes and management of invasive procedures in participants with hemophilia A post gene therapy: a post hoc analysis of the GENEr8-1 phase III trial. Therapeutic Advances in Hematology. 15. 1574222405–1574222405. 1 indexed citations

Chawla, Neal Shiv, et al.. (2023). 1925P Results of SOC-2082 phase II study using metronomic gemcitabine, doxorubicin, and docetaxel plus nivolumab as second/third-line therapy for advanced leiomyosarcoma. Annals of Oncology. 34. S1035–S1035. 1 indexed citations

Mahlangu, Johnny, Susan Shapiro, Margareth C. Ozelo, et al.. (2023). Efficacy and safety of valoctocogene roxaparvovec gene transfer for severe hemophilia A: results from the GENEr8-1 three-year analysis. Hämostaseologie. 43(S 01). S96–S96. 1 indexed citations

Mahlangu, Johnny, Annette von Drygalski, Susan Shapiro, et al.. (2023). OC 20.1 Bleeding, FVIII Activity, and Safety 3 Years After Gene Transfer with Valoctocogene roxaparvovec: Results from GENEr8-1. Research and Practice in Thrombosis and Haemostasis. 7. 100459–100459. 2 indexed citations

Chawla, Sant P., et al.. (2023). Activity of TNT: a phase 2 study using talimogene laherparepvec, nivolumab and trabectedin for previously treated patients with advanced sarcomas (NCT# 03886311). Frontiers in Oncology. 13. 1116937–1116937. 10 indexed citations

Barnes, R. F. W., et al.. (2023). Consistency of serial ultrasonographic joint tissue measurements by the Joint tissueActivity and Damage Exam (JADE) protocol in relation to hemophilic joint health parameters. BMC Musculoskeletal Disorders. 24(1). 299–299. 4 indexed citations

10.

Cuker, Adam, Miguel A. Escobar, M. Elaine Eyster, et al.. (2022). Postoperative bleeding complications in patients with hemophilia undergoing major orthopedic surgery: A prospective multicenter observational study. Journal of Thrombosis and Haemostasis. 20(4). 857–865. 21 indexed citations

11.

Witkop, Michelle, Anne T. Neff, Tyler W. Buckner, et al.. (2017). Self‐reported prevalence, description and management of pain in adults with haemophilia: methods, demographics and results from the Pain, Functional Impairment, and Quality of life (P‐FiQ) study. Haemophilia. 23(4). 556–565. 99 indexed citations

12.

Kempton, Christine L., Michael Recht, Anne T. Neff, et al.. (2017). Impact of pain and functional impairment in US adults with haemophilia: Patient‐reported outcomes and musculoskeletal evaluation in the pain, functional impairment and quality of life (P‐FiQ) study. Haemophilia. 24(2). 261–270. 42 indexed citations

13.

Wang, Michael, María Román, Pratima Chowdary, Doris Quon, & Kim Schafer. (2016). Physical activity in individuals with haemophilia and experience with recombinant factor VIII Fc fusion protein and recombinant factor IX Fc fusion protein for the treatment of active patients. Blood Coagulation & Fibrinolysis. 27(7). 737–744. 20 indexed citations

14.

Powell, Jerry S., Neil C. Josephson, Doris Quon, et al.. (2012). Safety and prolonged activity of recombinant factor VIII Fc fusion protein in hemophilia A patients. Blood. 119(13). 3031–3037. 171 indexed citations

15.

Valentino, Leonard A., Vasily Mamonov, Andrzej Hellmann, et al.. (2011). A randomized comparison of two prophylaxis regimens and a paired comparison of on‐demand and prophylaxis treatments in hemophilia A management. Journal of Thrombosis and Haemostasis. 10(3). 359–367. 203 indexed citations

16.

Kurth, Margaret, John Puetz, Peter A. Kouides, et al.. (2011). The use of a single von Willebrand factor‐containing, plasma‐derived FVIII product in hemophilia A immune tolerance induction: the US experience. Journal of Thrombosis and Haemostasis. 9(11). 2229–2234. 39 indexed citations

17.

Quon, Doris, et al.. (2010). Safety and efficacy of plasma‐derived coagulation factor IX concentrate (AlphaNine^® SD) in patients with haemophilia B undergoing surgical intervention: a single institution retrospective analysis. Haemophilia. 17(1). e196–201. 6 indexed citations

18.

Quon, Doris & Barbara A. Konkle. (2009). How we treat: Haematuria in adults with haemophilia. Haemophilia. 16(4). 683–685. 11 indexed citations

19.

Saab, Sammy, et al.. (2004). Same day outpatient transjugular liver biopsies in haemophilia. Haemophilia. 10(6). 727–731. 16 indexed citations

20.

Quon, Doris, et al.. (1996). Transcription in the early diverging eukaryoteTrichomonas vaginalis: An unusual RNA polymerase II and α-amanitin-resistant transcription of protein-coding genes. Journal of Molecular Evolution. 43(3). 253–262. 28 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact